Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825

Following a strategic portfolio review, Boundless Bio (BOLD) has elected to cease enrollment of the Phase 1/2 Potentiate trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor and BBI-825, its oral, selective RNR inhibitor, in oncogene-amplified cancers. “This decision reflects market considerations, clinical data, and the Company’s prioritization of programs with the greatest potential to deliver meaningful clinical impact and long-term value,” the company said.